Toviaz
NDC 54868-6156
Product Information
Toviaz is a NDA-approved product labeled by Physicians Total Care, Inc.. This medication is used to treat an overactive bladder. It is supplied as a blue product. This product entry covers the primary NDC 54868-6156 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
FS
Code Structure Chart
Product Details
What is NDC 54868-6156?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- FESOTERODINE FUMARATE (UNII: EOS72165S7)
- FESOTERODINE (UNII: 621G617227) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- GLYCERYL BEHENATE (UNII: R8WTH25YS2)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- INDIGOTINDISULFONATE SODIUM (UNII: D3741U8K7L)
- ALUMINUM OXIDE (UNII: LMI26O6933)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- LECITHIN, SOYBEAN (UNII: 1DI56QDM62)
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)
- POLYVINYL ALCOHOL (UNII: 532B59J990)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- XYLITOL (UNII: VCQ006KQ1E)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 810071 - fesoterodine fumarate 4 MG 24HR Extended Release Oral Tablet
- RxCUI: 810071 - 24 HR fesoterodine fumarate 4 MG Extended Release Oral Tablet
- RxCUI: 810071 - fesoterodine fumarate 4 MG 24 HR Extended Release Oral Tablet
- RxCUI: 810075 - Toviaz 4 MG 24HR Extended Release Oral Tablet
- RxCUI: 810075 - 24 HR fesoterodine fumarate 4 MG Extended Release Oral Tablet [Toviaz]
* Please review the full disclaimer at the bottom of this page.